Retatrutide (LY3437943) Triple Agonist (GLP-1/GIP/Glucagon) Retatrutide (LY3437943) is an investigational triple hormone receptor agonist developed by Eli Lilly that activates GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors
10.1002/anie.200900185 4 BaloghL
Without those pieces, you risk ending up lighter, but weakerskinny fat instead of strong and healthy
Consistent use can lead to increased fat loss, especially around the abdomen
Yes, the cortisol gut microbiome connection matters because gut bacteria help regulate estrogen metabolism, cortisol balance, inflammation, and emotional stability, all of which change during menopause